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We previously reported that cattle were affected by a
prion disorder that differed from bovine spongiform
encephalopathy (BSE) by showing distinct molecular fea-
tures of disease-associated protease-resistant prion pro-
tein (PrPres). We show that intracerebral injection of such
isolates into C57BL/6 mice produces a disease with preser-
vation of PrPres molecular features distinct from BSE.
Until recently, transmissible spongiform encephalopa-thy (TSE) in cattle was believed to be caused by a sin-
gle strain of infectious agent identified at the beginning of
a foodborne epidemic of bovine spongiform encephalopa-
thy (BSE). Characterization of the infectious agent associ-
ated with BSE showed unique features. These include
defined incubation periods and distribution of brain lesions
after transmission to wild-type mice, not only directly
from cattle, but also after natural or experimentally
induced cross-species transmission (1,2). The uniform fea-
tures of the disease in cattle have also been shown by
analysis of the distribution of neurodegenerative brain
lesions at different places during the BSE epidemic (3,4).
Western blot analyses of protease-resistant prion pro-
tein (PrPres) accumulating in the brains of animals and
humans with BSE have demonstrated specific molecular
features. These include a low molecular mass of unglyco-
sylated PrPres with high proportions of diglycosylated
PrPres (5,6). However, recent studies reported cases of
prion abnormalities in cattle with different PrPres features
(7,8). Three cattle isolates from France have been report-
ed, characterized by a higher apparent molecular mass of
unglycosylated PrPres (H-type isolates) and decreased lev-
els of diglycosylated PrPres when compared with BSE iso-
lates (7). In addition. only PrPres from H-type isolates were
labeled by monoclonal antibody P4 with defined PrPres N
terminus epitope specificity, in contrast with PrPres from
BSE isolates, which suggests a different cleavage by pro-
teinase K of the disease-associated protein (9).
Twenty years after identification of the BSE epidemic
in cattle, the origin of the BSE agent remains controver-
sial (10,11). Researchers have often considered the most
likely source to be a recycled infectious agent derived
from prion-associated diseases found in other species,
such as scrapie in sheep and goats. The recent description
of unusual phenotypes of bovine prion diseases distinct
from BSE is therefore puzzling (7). This situation has
been reinforced by a second bovine amyloidotic spongi-
form encephalopathy found in cattle in Italy (8). However,
whether such cases of bovine prion disorders were trans-
missible, and to what extent the infectious agent caused
specific features distinct from BSE, have not been
demonstrated.
The Study
Experimental groups of 20 (4- to 6-week old) C57BL/6
female mice (Charles River, L’Arbresle, France) were
injected intracerebrally with 20 µL of 10% (weight/vol-
ume) homogenates per mouse prepared from brain stem
samples of 3 cattle TSE isolates. Two of the isolates were
characterized, as previously described (7), by a higher
molecular mass of unglycosylated PrPres (H-type isolates)
and labeling with P4 monoclonal antibody (Table). A typi-
cal cattle BSE isolate was also analyzed. Mice were
housed and cared for in an appropriate biohazard preven-
tion area (A3) according to European (directive
86/609/EEC) and French ethical committee (decree
87–848) guidelines. Mice were checked at least weekly for
neurologic clinical signs and were killed when they exhib-
ited signs of distress or confirmed evolution of clinical
signs. The whole brain of every second mouse was frozen
and stored at –80°C before Western blot analysis. The
other brains were fixed in 4% paraformaldehyde for other
histopathologic studies.
Frozen mouse brain tissues and fixed brain tissues were
examined by Western blot analysis and immunohistochem-
ical tests as previously described (12,13). PrPres extracted
from half of whole brain was detected with monoclonal
antibodies Sha31 (1:10 from TeSeE sheep/goat Western
blot, Bio-Rad, Hercules, CA, USA) (14) and (340 ng/mL)
(15). These antibodies are directed against the 144-
WEDRYYRE-151 and 88-WGQGG-92 murine amino
acid PrP sequences, respectively. Antibody 12B2, which
has an N-terminal specificity similar to that of monoclon-
al antibody P4, shows poor binding to BSE-derived PrPres,
but unlike P4, binds with high affinity to prion protein
from most mammalian species, including mice and cattle.
Bound antibodies were detected by using enhanced enzy-
matic chemiluminescence (Amersham, Little Chalfont,
UK) or Supersignal (Pierce, Rockford, IL, USA) and visu-
alized either on film (Biomax, Eastman Kodak, Rochester,
NY, USA) or directly in an image analysis system
(Versadoc, Bio-Rad). Molecular masses of PrPres glyco-
forms were determined as the average of the center posi-
tions of the bands from at least 3 repeated electrophoretic
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procedures, as measured by comparison with a biotinylat-
ed marker (B2787, Sigma, Saint Louis, MO, USA)
included on each gel. Immunologic reactivities of antibod-
ies 12B2 and Sha31 were compared in Western blots run in
parallel with the same samples with both antibodies.
After intracerebral injection of cattle brain samples into
C57BL/6 mice, disease was observed in mice with the 2 H-
type isolates, as well as with the BSE sample. Survival
periods of mice and results of PrPres detection among mice
analyzed by Western blot are shown in the Table.
Western blot analysis of PrPres from H-type–infected
mouse brains in comparison with BSE-infected mice is
shown in Figure 1. All positive mice in the same experi-
mental group showed the same Western blot pattern. This
pattern showed higher molecular mass PrPres glycoforms in
mice infected with H-type isolates than in mice infected
with a typical BSE agent (1.1- to 1.5-Da difference in the
unglycosylated PrPres (Figure 1A). Studies of PrPres pro-
tease cleavage showed that only the PrPres of mice infected
with H-type isolates was recognized by antibody 12B2
(Figure 1B). This finding is in contrast to the result
obtained with monoclonal antibody Sha31 directed against
an epitope in the central region of the protein, which
showed that the 12B2 epitope was preserved in H-
type–infected mice. Thus, the molecular features of H-type
cattle isolates, which are distinct from those of the BSE
agent, were maintained after development of disease in
mice.
Histopathologic analysis showed vacuolar lesions in
the thalamus (Figure 2A) that were absent from the hypo-
thalamus, cochlear nucleus, and superior collicules. These
3 neuroanatomic sites were severely affected in C57BL/6
mice brain after primary passage of the BSE agent, as we
and others have reported (1). Abnormal PrP was detected
only in amyloid plaques (Figure 2B), in contrast to what
was reported after BSE transmission in C57BL/6 mice (1).
Conclusions
Our data show that the recently identified bovine H-
type isolates involve an infectious agent that can induce
development of a disease across a species barrier, while
maintaining the specific associated PrPres molecular signa-
ture. This evidence in favor of a new bovine prion strain in
cattle suggests that BSE is not the only transmissible prion
disease in cattle. The origin of such cases has not been
determined (7). These cases suggest either the existence of
alternative origins of such diseases in cattle or phenotypic
changes of PrPres after infection with the BSE agent.
However, based on analysis of molecular features of prion
diseases in cattle, this situation is similar to that in humans
(5), in which different subtypes of sporadic Creutzfeldt-
Jakob disease agents are found.
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Figure 1. Western blot analysis of disease-associated prion pro-
tein (PrPres) from proteinase K–treated brain homogenates of
C57BL/6 mice infected with type H (lanes 2 and 4) or bovine
spongiform encephalopathy isolates (lanes 3 and 5). PrPres of mice
infected with an experimental scrapie strain (C506M3) (6) was
used as a control (lane 1). Monoclonal antibodies used for detec-
tion of PrPres were Sha31 in panel A and 12B2 in panel B. Lane M,
molecular mass markers: 39.8, 29, 20.1, and 14.3 kDa.
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Figure 2. Histopathologic analysis of brain of a C57BL/6 mouse
infected with a type H isolate.  A) Characteristic vacuolar lesions in
the thalamus (hematoxylin and eosin stained, scale bar = 60 µm).
B) Immunohistochemical analysis of prion protein with monoclon-
al antibody 12B2 (diluted 1:200) shows the absence of granular
deposition, but the presence of plaques in the thalamus. The inset
shows that plaques are amyloids since they bind Congo red and
show birefringence in polarized light (scale bar = 60 µm, scale bar
in inset = 16 µm).
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